Stock Financial Ratios

XOMA / XOMA Corporation financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)843.66
Enterprise Value ($M)405.44
Book Value ($M)174.55
Book Value / Share6.81
Price / Book4.94
NCAV ($M)179.75
NCAV / Share7.01
Price / NCAV9.25
Income Statement (mra) ($M)
Net Income12.12
Balance Sheet (mrq) ($M)
Cash & Equivalents100.80
Cash / Share3.93
Quick Ratio4.31
Current Ratio4.31
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.07
Return on Assets (ROA)0.06
Return on Equity (ROE)0.07
Identifiers and Descriptors
Central Index Key (CIK)1062292
Industry Groups
SIC 596 - Nonstore Retailers
Other Related CUSIPS
Share Statistics
Common Shares Outstanding (M)25.70
Scoring Models
Piotroski F Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Additional Paid In Capital Per Share6.98
Liabilities Other Non Current Per Share0.05
Inventory Work In Progress Per Share0.00
Property Plant And Equipment Per Share0.43
Long Term Debt Per Share0.00
Cash And Equivalents Per Share3.93
Treasury Stock Per Share0.00
Equity Per Share6.66
Debt Per Share0.00
Goodwill Per Share1.99
Accounts Receivable Per Share0.62
Intangibles Per Share0.18
Inventory Per Share0.00
Assets Other Non Current Per Share0.00
Liabilities Current Per Share1.04
Liabilities And Stock Equity Per Share7.88
Assets Current Per Share4.80
Accumulated Depreciation And Depletion Per Share0.00
Property Plant And Equipment Net Per Share0.43
Cash Per Share3.93
Minority Interest Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Retained Earnings Per Share-0.33
Inventory Raw Materials Per Share0.00
Assets Other Current Per Share0.00
Assets Per Share7.51
Inventory Finished Goods Per Share0.00
Accounts Payable Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Liabilities Per Share1.21

Related News Stories

Bristol-Myers (BMY) Reports Data from CheckMate-142 Study

19h zacks
Bristol-Myers Squibb Company (BMY - Free Report) announced new data from a cohort of the phase II CheckMate -142 study on Opdivo. (40-0)

Acorda Therapeutics (ACOR) Jumps: Stock Rises 8.8%

21h zacks
Acorda Therapeutics, Inc. (ACOR - Free Report) was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company—as the stock is now up 25.06% in the past one-month time frame. (30-0)

The Ideal Stock Evaluation System?

23h seekingalpha
About two and a half years ago, I had a revelation. I’d been losing money for years, choosing the wrong stocks, buying and selling them at the wrong times. But I suddenly realized that the key to success in the stock market is not just screening stocks on a few factors but instead to systematically evaluate every stock from as many angles as possible before buying it. Since I put my initial evaluation system in place around Halloween 2015, my compound annual returns have been 47%--a total growth of 135% in 27 months. (209-1)

Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It?

2018-01-17 zacks
Shares of Novo Nordisk (NVO - Free Report) hit a new 52-week high of $55.72 on Jan 16, before eventually closing the day at $55.31. Shares of Novo Nordisk have gained 53.5% over a year while the industry registered an increase of 20.6%. (39-0)

3 Pharma and Biotech Stocks to Watch Out for in 2018

2018-01-15 zacks
2017 turned out to be a pretty good year for pharma and biotech stocks with the Nasdaq Biotechnology index and the NYSE ARCA Pharmaceutical index gaining 18.7% and 11.8%, respectively. Although the industry continued to face headwinds in the form of drug pricing scrutiny, pricing pressure, increasing competition, concerns regarding Amazon’s interest in entering the healthcare arena, fewer-than-expected acquisition deals and major pipeline setbacks, there were some positive developments as well. (94-0)

CUSIP: 98419J107